Discovery of dual tubulin-NEDDylation inhibitors with antiproliferative activity

J Enzyme Inhib Med Chem. 2023 Dec;38(1):166-175. doi: 10.1080/14756366.2022.2136173.

Abstract

Although various dual-target tubulin inhibitors have been designed and synthesised, no dual tubulin-NEDDylation inhibitors as antiproliferative agents were reported so far. In this work, a series of trimethoxyphenyl analogues as potential dual tubulin-NEDDylation inhibitors were synthesised and evaluated for their antiproliferative activity. Among them, compound C11 exhibited the most potent inhibitory activity with IC50 values of 1.17, 2.48, and 1.47 μM against HepG2, PC3, and MCF7 cells, respectively. In addition, it displayed the potent inhibitory activity against tubulin with an IC50 value of 2.40 μM and obviously inhibited tubulin polymerisation in HepG2 cells. Furthermore, C11 inhibited NEDDylation by a ATP-dependent manner. Molecular docking studies revealed that the methoxy group and dithiocarbamate group of C11 could form hydrogen bonds with residues of tubulin and E1 NEDD8-activating enzyme (NAE). These results suggested that compound C11 was a dual tubulin-NEDDylation inhibitor with antiproliferative activity.

Keywords: NEDDylation; Tubulin; antiproliferative activity; molecular docking.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • Humans
  • Molecular Docking Simulation
  • Molecular Structure
  • Structure-Activity Relationship
  • Tubulin / metabolism
  • Tubulin Modulators* / chemistry
  • Tubulin Modulators* / pharmacology

Substances

  • Tubulin Modulators
  • Tubulin
  • Antineoplastic Agents

Grants and funding

This work was supported by “the Fundamental Research Funds for the Central Universities” [2022-JYB-XJSJJ025].